Rationale and design of dal-VESSEL: A study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation

Current Medical Research and Opinion

Volumn 27, Issue 1, 2011, Pages 141-150

  Kastelein, John J P ^a   Duivenvoorden, Raphaël ^a   Deanfield, John ^b   De Groot, Eric ^a   Jukema, J Wouter ^c   Kaski, Juan Carlos ^d   Münzel, Thomas ^e   Taddei, Stefano ^f   Lehnert, Valerie ^g   Burgess, Tracy ^h   Kallend, David ^g   Lüscher, Thomas F ⁱ  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF PISA   (Italy)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h HOFFMANN LA ROCHE INC   (United States)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Atherosclerosis; CETP inhibition; Endothelial function; Flow mediated dilatation

Indexed keywords

DALCETRAPIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PLACEBO;

ADULT; AGED; ARTERY BLOOD FLOW; ARTICLE; B SCAN; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; VASCULAR ENDOTHELIUM; VASODILATATION;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTICHOLESTEREMIC AGENTS; BRACHIAL ARTERY; CORONARY DISEASE; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PLACEBOS; RATIONALIZATION; REGIONAL BLOOD FLOW; RESEARCH DESIGN; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME; VASODILATION; YOUNG ADULT;

EID: 78650347148     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.536207     Document Type: Article

References (35)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74
2. World Health Organization. The global burden of Disease report: 2004 update. http://www.who.int/healthinfo/global-burden-disease/GBD-report-2004 update-full.pdf
3. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-445.
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al.; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10
5. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46:1225-8
6. Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006;47:492-9
7. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
8. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88
9. Klerkx AH, El Harchaoui K, van der Steeg WA, et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogen-esis. Arterioscler Thromb Vasc Biol 2006;26:706-15
10. Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009;104:82-91
11. Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010;31:480-8
12. Kuivenhoven JA, de Grooth GJ, KawamuraH, etal. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
13. Barter PJ, Caulfield M, Eriksson M, etal.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-22
14. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515-22
15. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008; 118:2506-14
16. Nissen SE, Tardif JC, Nicholls SJ, et al.; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
17. Kastelein JJ, van Leuven SI, Burgess L, et al.; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
18. Bots ML, Visseren FL, Evans GW, et al.; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370:153-60
19. Sofat R, Hingorani AD, Smeeth L, etal. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010;121:52-62
20. Kon V, Jabs K. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 2004;13:291-7
21. Stroes ES, Kastelein JJ, Benardeau A, et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin- aldosterone system in rats. Br J Pharmacol 2009;158:1763-70
22. Niesor EJ, von der Marck E, Brousse M, et al. Inhibition of cholesteryl ester transfer protein (CETP): different in vitro characteristics of dalcetrapib and torcetrapib. Atherosclerosis 2008;199:231
23. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesterol ester transfer protein activity maintains efficient pre-j6-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010;51:3443-3454
24. Schwartz GG, Olsson AG, Ballantyne CM, et al.; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-901
25. Doshi SN, Naka KK, Payne N, et al. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin Sci (Lond) 2001;101:629-35
26. Mullen MJ, Kharbanda RK, Cross J, et al. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res 2001;88:145-51
27. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41
28. Yeboah J, Crouse JR, Hsu F-C, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults. The Cardiovascular Health Study. Circulation 2007;115:2390-7
29. Gokce N, Keaney Jr JF, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-72
30. Brevetti G, Silvestro A, Schiano V, et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral artery disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108:2093-8
31. Gokce N, Keaney Jr JF, Hunter LM. Predictive value of noninvasively determined endothelial dysfunction for long term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-75
32. Muiesan ML, Salvetti M, Monteduro C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999;33:575-80
33. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7
34. Jodoin I, Bussières LM, Tardif JC, et al. Effect of a short-term primary prevention program on endothelium-dependent vasodilation in adults at risk for atherosclerosis. Can J Cardiol 1999;15:83-8
35. Raitakari OT, Rö nnemaa T, Jä rvisalo MJ, et al. Endothelial function in healthy 11-year-old children after dietary intervention with onset in infancy: the Special Turku Coronary Risk Factor Intervention Project for children (STRIP). Circulation 2005;112:3786-94